146 related articles for article (PubMed ID: 9212919)
21. Review of in vivo pharmacokinetics and toxicology of phosphorothioate oligonucleotides.
Srinivasan SK; Iversen P
J Clin Lab Anal; 1995; 9(2):129-37. PubMed ID: 7714665
[No Abstract] [Full Text] [Related]
22. Spinal distribution and metabolism of 2'-O-(2-methoxyethyl)-modified oligonucleotides after intrathecal administration in rats.
Butler M; Hayes CS; Chappell A; Murray SF; Yaksh TL; Hua XY
Neuroscience; 2005; 131(3):705-15. PubMed ID: 15730875
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetic properties of several novel oligonucleotide analogs in mice.
Crooke ST; Graham MJ; Zuckerman JE; Brooks D; Conklin BS; Cummins LL; Greig MJ; Guinosso CJ; Kornbrust D; Manoharan M; Sasmor HM; Schleich T; Tivel KL; Griffey RH
J Pharmacol Exp Ther; 1996 May; 277(2):923-37. PubMed ID: 8627575
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics of antisense oligonucleotides.
Agrawal S; Temsamani J; Galbraith W; Tang J
Clin Pharmacokinet; 1995 Jan; 28(1):7-16. PubMed ID: 7712663
[TBL] [Abstract][Full Text] [Related]
25. Tissue distribution and physiologically based pharmacokinetics of antisense phosphorothioate oligonucleotide ISIS 1082 in rat.
Peng B; Andrews J; Nestorov I; Brennan B; Nicklin P; Rowland M
Antisense Nucleic Acid Drug Dev; 2001 Feb; 11(1):15-27. PubMed ID: 11258618
[TBL] [Abstract][Full Text] [Related]
26. Distribution and stability of antisense phosphorothioate oligonucleotides in rodent brain following direct intraparenchymal controlled-rate infusion.
Broaddus WC; Prabhu SS; Gillies GT; Neal J; Conrad WS; Chen ZJ; Fillmore H; Young HF
J Neurosurg; 1998 Apr; 88(4):734-42. PubMed ID: 9525721
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetics of an antisense phosphorothioate oligodeoxynucleotide against rev from human immunodeficiency virus type 1 in the adult male rat following single injections and continuous infusion.
Iversen PL; Mata J; Tracewell WG; Zon G
Antisense Res Dev; 1994; 4(1):43-52. PubMed ID: 8061515
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics, metabolism, and elimination of a 20-mer phosphorothioate oligodeoxynucleotide (CGP 69846A) after intravenous and subcutaneous administration.
Phillips JA; Craig SJ; Bayley D; Christian RA; Geary R; Nicklin PL
Biochem Pharmacol; 1997 Sep; 54(6):657-68. PubMed ID: 9310342
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics and blood-brain barrier transport of [3H]-biotinylated phosphorothioate oligodeoxynucleotide conjugated to a vector-mediated drug delivery system.
Wu D; Boado RJ; Pardridge WM
J Pharmacol Exp Ther; 1996 Jan; 276(1):206-11. PubMed ID: 8558431
[TBL] [Abstract][Full Text] [Related]
30. Antisense oligonucleotide inhibitors for the treatment of cancer: 1. Pharmacokinetic properties of phosphorothioate oligodeoxynucleotides.
Geary RS; Leeds JM; Henry SP; Monteith DK; Levin AA
Anticancer Drug Des; 1997 Jul; 12(5):383-93. PubMed ID: 9236854
[No Abstract] [Full Text] [Related]
31. Disposition of the 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats.
Cossum PA; Sasmor H; Dellinger D; Truong L; Cummins L; Owens SR; Markham PM; Shea JP; Crooke S
J Pharmacol Exp Ther; 1993 Dec; 267(3):1181-90. PubMed ID: 8166890
[TBL] [Abstract][Full Text] [Related]
32. In vitro pharmacokinetics of phosphorothioate antisense oligonucleotides.
Crooke RM; Graham MJ; Cooke ME; Crooke ST
J Pharmacol Exp Ther; 1995 Oct; 275(1):462-73. PubMed ID: 7562586
[TBL] [Abstract][Full Text] [Related]
33. Mixed-backbone oligonucleotides as second generation antisense oligonucleotides: in vitro and in vivo studies.
Agrawal S; Jiang Z; Zhao Q; Shaw D; Cai Q; Roskey A; Channavajjala L; Saxinger C; Zhang R
Proc Natl Acad Sci U S A; 1997 Mar; 94(6):2620-5. PubMed ID: 9122245
[TBL] [Abstract][Full Text] [Related]
34. Quantitative analysis of phosphorothioate oligonucleotides in biological fluids using direct injection fast anion-exchange chromatography and capillary gel electrophoresis.
Bourque AJ; Cohen AS
J Chromatogr B Biomed Appl; 1994 Dec; 662(2):343-9. PubMed ID: 7719488
[TBL] [Abstract][Full Text] [Related]
35. Sequence dependency of the internalization and distribution of phosphorothioate oligonucleotides in vascular smooth muscle cells.
Etore F; Tenu JP; Teiger E; Adnot S; Lonchampt MO; Pirotzki E; Le Doan T
Biochem Pharmacol; 1998 May; 55(9):1465-73. PubMed ID: 10076539
[TBL] [Abstract][Full Text] [Related]
36. Pharmacology and toxicology of phosphorothioate oligonucleotides in the mouse, rat, monkey and man.
Iversen PL; Copple BL; Tewary HK
Toxicol Lett; 1995 Dec; 82-83():425-30. PubMed ID: 8597088
[TBL] [Abstract][Full Text] [Related]
37. Development of a novel scintillation proximity competitive hybridization assay for the determination of phosphorothioate antisense oligonucleotide plasma concentrations in a toxicokinetic study.
de Serres M; McNulty MJ; Christensen L; Zon G; Findlay JW
Anal Biochem; 1996 Jan; 233(2):228-33. PubMed ID: 8789723
[TBL] [Abstract][Full Text] [Related]
38. Biodistribution and metabolism of internally 3H-labeled oligonucleotides. I. Comparison of a phosphodiester and a phosphorothioate.
Sands H; Gorey-Feret LJ; Cocuzza AJ; Hobbs FW; Chidester D; Trainor GL
Mol Pharmacol; 1994 May; 45(5):932-43. PubMed ID: 8190109
[TBL] [Abstract][Full Text] [Related]
39. In vivo distribution and metabolism of a phosphorothioate oligonucleotide within rat liver after intravenous administration.
Graham MJ; Crooke ST; Monteith DK; Cooper SR; Lemonidis KM; Stecker KK; Martin MJ; Crooke RM
J Pharmacol Exp Ther; 1998 Jul; 286(1):447-58. PubMed ID: 9655890
[TBL] [Abstract][Full Text] [Related]
40. Comparison of cellular binding and uptake of antisense phosphodiester, phosphorothioate, and mixed phosphorothioate and methylphosphonate oligonucleotides.
Zhao Q; Matson S; Herrera CJ; Fisher E; Yu H; Krieg AM
Antisense Res Dev; 1993; 3(1):53-66. PubMed ID: 8495106
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
